menu search

CTABF / Canntab Therapeutics appoints Hamish Sutherland as strategic business consultant

Canntab Therapeutics appoints Hamish Sutherland as strategic business consultant
Canntab Therapeutics Ltd said it has appointed Hamish Sutherland as a strategic business consultant to develop additional sales and distribution channels for the company's products and to assist it in reaching strategic partnerships in the cannabis industry. A seasoned veteran of the legal cannabis industry in Canada with over nine years of experience, Sutherland's past achievements include the role of founding chief operating officer of Bedrocan Canada Inc., delivering over $750 million in investor value and overseeing the building and commissioning of two licensed facilities, including a 52,000 square foot state-of-the-art automated facility in suburban Toronto. Read More
Posted: Apr 13 2022, 08:44
Author Name: Proactive Investors
Views: 101977

CTABF News  

Canntab Therapeutics seeks to move manufacturing process as Markham lease expires

By Proactive Investors
November 22, 2022

Canntab Therapeutics seeks to move manufacturing process as Markham lease expires

Canntab Therapeutics Ltd (CSE:PILL, OTCQB:CTABF) has provided an update on several matters impacting the company, including plans to move its manufact more_horizontal

Canntab Therapeutics provides update on recent product delivery of its cannabinoid solutions to the Nova Scotia Liquor Corporation

By Proactive Investors
August 22, 2022

Canntab Therapeutics provides update on recent product delivery of its cannabinoid solutions to the Nova Scotia Liquor Corporation

Canntab Therapeutics Limited has provided an update on the recent product delivery of its unique pharmaceutical cannabinoid solutions to the Nova Scot more_horizontal

Canntab Therapeutics appoints Hamish Sutherland as strategic business consultant

By Proactive Investors
April 13, 2022

Canntab Therapeutics appoints Hamish Sutherland as strategic business consultant

Canntab Therapeutics Ltd said it has appointed Hamish Sutherland as a strategic business consultant to develop additional sales and distribution chan more_horizontal

Canntab Therapeutics inks affiliate deal with independent pharmacy owners in Ontario

By Proactive Investors
March 23, 2022

Canntab Therapeutics inks affiliate deal with independent pharmacy owners in Ontario

Canntab Therapeutics Ltd (CSE:PILL, OTCQB:CTABF) announced that it has entered into an affiliate agreement with OnPharm-United, a 600-plus network of more_horizontal

Canntab Therapeutics closes non-brokered private placement of secured convertible debentures for gross proceeds of $1,312,000

By Proactive Investors
February 2, 2022

Canntab Therapeutics closes non-brokered private placement of secured convertible debentures for gross proceeds of $1,312,000

Canntab Therapeutics Ltd (CSE:PILL, OTCQB:CTABF) said it has closed a non-brokered private placement of secured convertible debentures of the company, more_horizontal

Canntab Therapeutics closes non-brokered private placement of secured convertible debentures for gross proceeds of $1,312,000

By Proactive Investors
February 2, 2022

Canntab Therapeutics closes non-brokered private placement of secured convertible debentures for gross proceeds of $1,312,000

Canntab Therapeutics Ltd (CSE:PILL, OTCQB:CTABF) said it has closed a non-brokered private placement of secured convertible debentures of the company, more_horizontal

Canntab Therapeutics closes non-brokered private placement of secured convertible debentures for gross proceeds of $1,312,000

By Proactive Investors
February 2, 2022

Canntab Therapeutics closes non-brokered private placement of secured convertible debentures for gross proceeds of $1,312,000

Canntab Therapeutics Ltd (CSE:PILL, OTCQB:CTABF) said it has closed a non-brokered private placement of secured convertible debentures of the company, more_horizontal


Search within

Pages Search Results: